Amalgamated Bank Has $7.93 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Amalgamated Bank lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 3.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,775 shares of the company’s stock after selling 2,110 shares during the quarter. Amalgamated Bank’s holdings in Moderna were worth $7,930,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Ashton Thomas Private Wealth LLC bought a new position in shares of Moderna in the second quarter worth $26,000. Cedar Wealth Management LLC raised its position in shares of Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares in the last quarter. Westside Investment Management Inc. bought a new stake in shares of Moderna during the 1st quarter worth approximately $32,000. Family Firm Inc. acquired a new stake in shares of Moderna during the 2nd quarter worth approximately $33,000. Finally, Rise Advisors LLC increased its stake in Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after acquiring an additional 286 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. HSBC raised Moderna from a “reduce” rating to a “hold” rating and set a $82.00 target price on the stock in a report on Wednesday, August 28th. Bank of America decreased their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research report on Friday, September 13th. Piper Sandler dropped their target price on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Hsbc Global Res raised shares of Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. Finally, Evercore ISI restated an “in-line” rating and issued a $120.00 target price on shares of Moderna in a research report on Thursday, June 27th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and an average price target of $100.44.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $117.08, for a total transaction of $1,756,200.00. Following the transaction, the director now directly owns 2,269,015 shares of the company’s stock, valued at $265,656,276.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. The disclosure for this sale can be found here. Insiders sold 93,158 shares of company stock valued at $11,167,312 over the last 90 days. Company insiders own 15.70% of the company’s stock.

Moderna Stock Down 2.6 %

Shares of NASDAQ MRNA opened at $68.02 on Friday. The company’s 50 day moving average price is $91.19 and its 200-day moving average price is $110.97. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The company has a market capitalization of $26.07 billion, a P/E ratio of -4.34 and a beta of 1.68.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the prior year, the firm posted ($3.62) earnings per share. The business’s quarterly revenue was down 29.9% compared to the same quarter last year. Equities analysts forecast that Moderna, Inc. will post -9.52 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.